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Objective. Beta-2-glycoprotein I (2GPI) consti-
tutes the major autoantigen in the antiphospholipid
syndrome (APS), a common acquired cause of arterial
and venous thrombosis. We recently described the novel
observation that 2GPI may exist in healthy individuals
in a free thiol (biochemically reduced) form. The pres-
ent study was undertaken to quantify the levels of total,
reduced, and posttranslationally modified oxidized
2GPI in APS patients compared to various control
groups.
Methods. In a retrospective multicenter analysis,
the proportion of 2GPI with free thiols in serum from
healthy volunteers was quantified. Assays for measure-
ment of reduced as well as total circulating 2GPI were
developed and tested in the following groups: APS (with
thrombosis) (n  139), autoimmune disease with or
without persistent antiphospholipid antibodies (aPL)
but without APS (n  188), vascular thrombosis without
APS or aPL (n  38), and healthy volunteers (n  91).
Results. Total 2GPI was significantly elevated in
patients with APS (median 216.2 g/ml [interquartile
range 173.3–263.8]) as compared to healthy subjects
(median 178.4 g/ml [interquartile range 149.4–227.5]
[P < 0.0002]) or control patients with autoimmune
disease or vascular thrombosis (both P < 0.0001). The
proportion of total 2GPI in an oxidized form (i.e.,
lacking free thiols) was significantly greater in the APS
group than in each of the 3 control groups (all P <
0.0001).
Conclusion. This large retrospective multicenter
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2774study shows that posttranslational modification of
2GPI via thiol-exchange reactions is a highly specific
phenomenon in the setting of APS thrombosis. Quanti-
fication of posttranslational modifications of 2GPI in
conjunction with standard laboratory tests for APS may
offer the potential to more accurately predict the risk of
occurrence of a thrombotic event in the setting of APS.
The antiphospholipid syndrome (APS) is an auto-
immune condition characterized by vascular thrombosis
of the arterial and/or venous systems as well as recurrent
miscarriages (1). Beta-2-glycoprotein I (2GPI) is the
major autoantigen in APS (2). A number of studies have
provided robust evidence that autoantibodies to 2GPI
are a significant risk factor for arterial thrombosis in
young adults (3,4). In vivo and ex vivo studies by multiple
groups have shown anti-2GPI autoantibodies to be
directly thrombogenic (5).
At present it is not possible to stratify the risk for
development of thrombosis in antiphospholipid antibody
(aPL)–positive patients based on clinical features or use
of currently available laboratory assays (6). The devel-
opment of novel assays that could be used to stratify
future thrombosis risk in patients with APS would hold
immense clinical utility in informing the decision as to
whether initiation of prophylactic therapy or intensifica-
tion of therapy is warranted.
Beta-2-glycoprotein I is an evolutionarily con-
served 50-kd protein circulating in the blood in relative
abundance (4 M) (7). The physiologic role of 2GPI
is pleiotropic, with functional studies implicating a role
in processes relating to coagulation (8), angiogenesis (9),
and clearance of apoptotic cells (10). The crystal struc-
ture of 2GPI, which has been ascertained based on the
purified native protein, reveals that it does not possess
free thiols (11,12). We have recently shown, however,
that in vivo 2GPI circulates in a free thiol form and
that this free thiol form of 2GPI is involved in the
protection of endothelial cells against oxidative stress–
induced cell injury (13). Beta-2-glycoprotein I can also
participate in redox thiol-exchange reactions by acting
as a substrate for oxidoreductase enzymes such as
thioredoxin 1 (14). However, the proportion of 2GPI
circulating in the reduced state is unknown. Also un-
known is whether the redox state of this autoantigen
differs in patients with pathogenic anti-2GPI antibodies
and a history of thrombosis.
In the present study we demonstrated that, in
serum/plasma derived from healthy subjects, 2GPI ex-
ists in a reduced biochemical state as the dominant
molecular phenotype. Detailed in vitro quantitative as-
says to assess the levels of total and reduced 2GPI were
developed and used to screen 450 samples. Levels of
both total and oxidized 2GPI were found to be elevated
in patients with APS as compared to disease and healthy
control groups. These findings have implications with
respect to understanding the antigenic drive for patho-
genic aPL, as well as the potential for development of
assays for purposes of thrombosis risk stratification.
PATIENTS AND METHODS
Patient samples. Samples were collected through an
international collaborative multicenter effort involving 5 cen-
ters (University of New South Wales [Sydney, Australia],
University of Athens [Athens, Greece], University College
London [London, UK], Tianjin Medical University [Tianjin,
China], and Hokkaido University School of Medicine [Sap-
poro, Japan]). An APS group, 2 disease control groups, and
1 healthy control group were studied. The disease control
groups consisted of an autoimmune disease group (with or
without aPL, but with no clinical features of APS) and a
clinical event control group (clinical features of APS, but no
aPL or autoimmune disease).
APS group. A total of 139 samples from patients with
APS were collected and analyzed (24 from Sydney, 38 from
Athens, 22 from London, and 55 from Sapporo). Every APS
patient fulfilled the revised consensus classification criteria for
vascular thrombosis–associated APS (1). All serologic tests for
aPL were performed using standard commercially available
kits and in accordance with the revised classification criteria. A
venous thrombotic event was diagnosed based on a combina-
tion of clinical assessment and appropriate imaging with either
Doppler ultrasonography or venography to confirm deep ve-
nous thrombosis, or isotope ventilation/perfusion scanning or
computed tomography (CT) (with or without angiography) to
confirm pulmonary embolism. An arterial event was diagnosed
based on clinical findings along with one or more of the
following: electrocardiographic evidence of myocardial isch-
emia or infarction, confirmation of infarction by brain CT or
magnetic resonance imaging, or confirmation of peripheral
vascular disease or arterial thrombosis by Doppler ultrasonog-
raphy or angiography.
Autoimmune disease control group. Of the 189 auto-
immune disease controls, samples from 188 were analyzed (42
from Sydney, 43 from Athens, 29 from London, and 74 from
Sapporo). One sample (from a patient with systemic lupus
erythematosus [SLE] and no aPL) was found to be deficient in
2GPI and was withdrawn from the study. Among the auto-
immune disease controls, 74 had persistently positive serologic
findings for aPL satisfying the serologic component of the APS
classification criteria (1), but did not have APS given the lack
of a clinical event. All patients with SLE fulfilled the American
College of Rheumatology revised classification criteria (15),
and those with Sjo ¨gren’s syndrome fulfilled the revised Euro-
pean classification criteria (16).
Clinical event control group. Thirty-eight samples from
aPL-negative patients with a clinical event were collected and
analyzed (26 from Sydney and 12 from Tianjin). Clinical events
were diagnosed as described above for the APS group.
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trols were collected, 92 of which were analyzed (28 from
Sydney, 35 from Athens, and 29 from Sapporo). One healthy
control sample was found to be deficient in 2GPI by standard
enzyme-linked immunosorbent assay (ELISA) and was with-
drawn from the study.
Demographic and clinical details of the study groups
are summarized in Table 1. Institutional ethics approval for
patient sampling was attained from each center participating in
the study, and informed consent was obtained from all subjects
prior to venipuncture. Assays were performed under blinded
conditions with regard to the underlying diagnosis.
Chemicals and reagents. HEPES and streptavidin
beads were purchased from Sigma. N-(3-maleimidylpropionyl)
biocytin (MPB) was purchased from Invitrogen. All other
chemicals were of reagent grade.
Proteins. Bovine serum albumin (BSA), alkaline phos-
phatase(AP)–conjugatedanti-mouseIgG,AP-conjugatedanti-
rabbit IgG, and AP-conjugated anti-human IgG were from
Sigma. Purified native human 2GPI was from Haematologic
Technologies and also sourced as a kind gift from Dr. Inger
Schousboe (University of Copenhagen, Denmark). Affinity-
purified murine IgG2 anti-2GPI monoclonal antibody (mAb)
4B2E7 (previously designated “mAb number 16”) and affinity-
purified rabbit anti-2GPI polyclonal antibody were produced
as previously described (17,18). Isotype control rabbit poly-
clonal IgG was purchased from BD PharMingen.
Assay for quantifying the absolute proportion of serum
2GPI that can be labeled with MPB. With the demonstration
that 2GPI exists in vivo in a reduced state with free thiols (13),
it was then pertinent to determine the absolute proportion of
total 2GPI that circulates in this reduced state. This was done
in experiments with a sample of pooled serum derived from 10
healthy volunteers. The sex and age distribution of the pooled
serum sample was chosen to match the APS disease group.
MPB-labeled and non–MPB-labeled serum samples
were acetone precipitated to remove free MPB as described
previously (13). The protein pellets were then dissolved in
phosphate buffered saline (PBS)–0.1% Tween to a final dilu-
tion of 4,000-fold (total volume 1,400 l), and streptavidin
beads (50 l) were added. After incubation with streptavidin
beads (1 hour at 4°C), the beads were removed by centrifuga-
tion for 2 minutes at 3,000g and the supernatants assayed for
2GPI. The proportion of 2GPI that was labeled with MPB
was calculated as (optical density at 405 nm [OD405]o ft h e
biotin-depleted MPB-labeled sample/OD405 of the biotin-
depleted non–MPB-labeled sample)  100. Validation of this
method is described in full in the supplementary information
(available in the online version of this article at http://
onlinelibrary.wiley.com/journal/10.1002/(ISSN)1529-0131).
Assay for quantifying total human 2GPI. A sandwich
ELISA for quantifying total 2GPI levels within serum/plasma
samples was performed based on a previously published
method (19), with modifications. Briefly, a high-binding 96-
Table 1. Demographic and clinical characteristics of the groups studied*
APS
Control groups
Autoimmune disease Clinical event Healthy
Patients 139 188 38 92†
Female 111 (79.9) 164 (87.2) 21 (55.3) 58 (63.0)
Age, median years 43 42 55.5 35
Race
Caucasian 82 110 26 56
Asian 56 77 12 36
Afro-Caribbean 1 1 0 0
Autoimmune disease
Total 75 (54.0) 188 (100) 1 (2.6) 0 (0)
SLE 58 (41.7) 106 (56.4) 1 (2.6) –
SS 8 (5.8) 30 (16.0) 1 (2.6) –
Other 10 (7.2) 58 (30.9) – –
Thrombosis
Total 139 (100) 0 (0) 38 (100) 0 (0)
Arterial 80 (57.6) – 21 (55.3) –
Venous 72 (51.8) – 20 (52.6) –
aPL positive
Total 139 (100) 74 (39.4) 0 (0) 0 (0)
aCL 93 (66.9) 43 (22.9) 0 (0) –
Anti-2GPI 79 (56.8) 29 (15.4) 0 (0) –
LAC 89 (64.0) 47 (25.0) 0 (0) –
Antithrombotic therapy
Total 103 (74.1) 54 (28.7) 29 (76.3) 0 (0)
Anticoagulant 58 (41.7) 52 (27.7) 6 (15.8) –
Antiplatelet 63 (45.3) 3 (1.6) 23 (60.5) –
* Except where indicated otherwise, values are the number (%). APS  antiphospholipid syndrome; SLE  systemic lupus erythematosus; SS 
Sjo ¨gren’s syndrome; aPL  antiphospholipid antibody; aCL  anticardiolipin antibody; LAC  lupus anticoagulant.
† One sample from this group was subsequently withdrawn from analysis because standard enzyme-linked immunosorbent assay revealed it to be
deficient in 2-glycoprotein I (2GPI).
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anti-human 2GPI (10 nM/well). Plates were washed 4 times
with PBS–0.1% Tween and then blocked with 2% BSA/PBS–
0.1% Tween for 1 hour at room temperature. Following
washing, 100 l of anti-human 2GPI mouse mAb (clone
4B2E7) was added (10 nM/well, diluted in 0.25% BSA/PBS–
0.1% Tween) and then 100 l of the patient sample diluted
4,000-fold in PBS–0.1% Tween was coincubated for 1 hour at
room temperature. After washing 4 times with PBS–0.1%
Tween, AP-conjugated goat anti-mouse IgG was added
(1:1,500 dilution) and incubated for 1 hour at room tempera-
ture, and samples read at OD405 after addition of chromogenic
substrate. An in-house standard, consisting of pooled serum
from 10 healthy controls, was used to construct a standard
curve for every ELISA. The level of 2GPI in the pooled-
serum in-house standard was determined initially using a
2GPI in-house standard curve and then validated with a
calibrator from a commercially available 2GPI quantification
kit (Hyphen BioMed). Each new batch of the pooled-serum
in-house standard was recalibrated against the commercial
calibrator. Samples were assayed in duplicate.
Within-plate coefficients of variation (CVs) for this
ELISA were calculated by running 10 duplicates of the same
patient sample on a single plate. Between-plate CVs were
calculated by taking 10 independent assays performed consec-
utively on separate days and calculating the CV based on the
variation of the number obtained by dividing the OD of the
standard at 4,000-fold dilution by the OD of the standard at
8,000-fold dilution for each plate.
Assay for measuring the relative amount of 2GPI
with free thiols within patient samples as compared to a
pooled-serum in-house standard sample. The amount of
2GPI with free thiols in patient samples relative to the
standard sample was assayed as previously described (13), with
minor modifications. Measurement of the amount of 2GPI
that is reduced is based on labeling of free thiols of 2GPI with
the biotin-conjugated selective free thiol binding reagent MPB,
capturing biotin-labeled proteins on a streptavidin plate, and
detecting the presence of MPB-labeled 2GPI with a specific
anti-2GPI mAb. The mean  SD within-plate CV for this
ELISA is 5.08  3.09%, and the between-plate CV is 6.25%
(13).
MPB (4 mM) was added to 50 l of patient plasma or
serum and incubated for 30 minutes at room temperature in
the dark with agitation, diluted 50-fold in 20 mM HEPES
buffer (pH 7.4), and incubated for a further 10 minutes at
room temperature in the dark. Unbound MPB was then
removed by acetone precipitation. The protein pellet was
resuspended in PBS–0.05% Tween (final dilution 100-fold).
The samples were then diluted a further 40-fold (4,000 times
final), added in duplicate to a streptavidin-coated 96-well plate
(100 l/well; Nunc), and incubated for 90 minutes at room
temperature. Prior to addition of MPB-labeled serum samples,
streptavidin-coated plates were washed 3 times with PBS–0.1%
Tween and blocked with 2% BSA/PBS–0.1% Tween. After
washing 3 times with PBS–0.1% Tween, the murine anti-2GPI
mAb (clone 4B2E7) was added (25 nM) and incubated for
1 hour at room temperature. After 3 further washings with
PBS–0.1% Tween, AP-conjugated goat anti-mouse IgG
(1:1,500 dilution) was added for 1 hour at room temperature
and samples read at 405 nm after addition of chromogenic
substrate. For each experiment, the pooled in-house standard
used for the above-described 2GPI quantification ELISA was
MPB labeled, acetone precipitated, and used as an internal
control and standard. The degree of MPB labeling in each
patient sample was expressed as a percentage of that observed
with the pooled in-house standard, after correction for the
total amount of 2GPI. The proportion of non–MPB-labeled
2GPI represents the oxidized form of the molecule.
Statistical analysis. Box plots were created to depict
the distributions of 2GPI across groups. Medians and inter-
quartile ranges (IQRs) were calculated. For comparisons
between individual samples, the Mann-Whitney U test was
used. Odds-ratios (ORs) and 95% confidence intervals (95%
CIs) of exposure or disease incidence were computed using
logistic regression. Adjustment for age and sex was carried out
to remove potential confounders linked to these predictors.
RESULTS
A significant proportion of 2GPI in vivo in
healthy volunteers circulates in the reduced form. We
have recently demonstrated that 2GPI circulates in vivo
in a reduced form (13), and we therefore wished to
determine the absolute proportion of 2GPI that is in
this biochemically reduced state. This was investigated
using a sample of human serum pooled from 10 healthy
volunteers. Figure 1 shows that a mean of 45.6% of
2GPI in pooled serum from healthy subjects was la-
beled with the biotin-conjugated free thiol binding re-
agent MPB. Validation of this method is demonstrated
in detail in Supplementary Figure 1, available in the
online version of this article at http://onlinelibrary.wiley.
com/journal/10.1002/(ISSN)1529-0131).
Total 2GPI levels are elevated in APS and are
associated with thrombogenic pathogenicity in aPL-
positive patients. Given that biochemically reduced
2GPI was found to represent a large proportion of
circulating 2GPI in healthy subjects, it was then rele-
vant to ascertain whether this level was altered in
patients with APS as compared to both disease control
and healthy control groups. Serum or plasma levels of
total 2GPI were quantified in each individual patient
sample so that a relative proportion of reduced and
oxidized 2GPI could be calculated for each sample.
The assay used for detecting total levels of 2GPI
in patient serum and plasma was optimized for use with
in-house anti-2GPI antibodies, as shown in Supplemen-
tary Figure 2 (http://onlinelibrary.wiley.com/journal/
10.1002/(ISSN)1529-0131). The within-plate CV for this
assay was 5.8% and the between-plate CV was 3.3%,
indicating good reproducibility.
The median level of total 2GPI in the healthy
control group was 178.4 g/ml (IQR 149.4–227.5) (n 
91). In addition to healthy controls, an autoimmune
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without aPL but without APS) and a clinical event
control group (thrombosis without aPL) were included,
as described above. As shown in Figure 2A, the concen-
tration of total 2GPI was significantly higher in the
APS group (median 216.2 g/ml [IQR 173.3–263.8])
(n  139) as compared to the healthy control group
(P  0.0002), the autoimmune disease control group
(P  0.0001), and the clinical event control group (P 
0.0001). Compared to healthy controls, cases were twice
as likely to have an elevated 2GPI level (defined as
plasma levels 200 g/ml). The effect remained after
adjustment for age and sex (OR 2.2 [95% CI 1.2–3.9]).
Given that the odds ratios of disease and of exposure can
be considered the same, this translates to a 2-fold
increase in thrombosis for patients with elevated 2GPI
Figure 2. Elevated levels of 2-glycoprotein I (2GPI) in patients with
the antiphospholipid syndrome (APS). A, Total 2GPI in the serum of
patients with thrombosis-associated APS and in the serum of patients
in the 3 control groups, i.e., healthy controls, patients with auto-
immune disease (AID) with or without antiphospholipid antibodies
(aPL) but without APS, and patients with clinical thrombotic events
without APS. B, Total 2GPI in the serum of patients in the APS group
who had an autoimmune disease compared to patients in the auto-
immune disease control group who were positive for aPL and patients
in the autoimmune disease control group who were negative for aPL.
Elevated levels of 2GPI were demonstrated only when aPL positivity was
combined with a thrombotic clinical event. Data are presented as box
plots, where the boxes represent the 25th to 75th percentiles, the lines
within the boxes represent the median, and the lines outside the boxes
represent the 10th and 90th percentiles. Circles indicate outliers.
Figure 1. Beta-2-glycoprotein I (2GPI) with free thiols represents a
large proportion of total circulating 2GPI in vivo. Pooled serum from
10 healthy volunteers was labeled with N-(3-maleimidylpropionyl)
biocytin (MPB) (4 mM) or treated with control buffer alone, after
which the MPB-labeled proteins were depleted by incubation with
streptavidin beads. Both samples were then centrifuged at 3,000g for
10 minutes to remove the beads, and an enzyme-linked immunosor-
bent assay for total 2GPI was performed on the supernatant of both
MPB-labeled and non–MPB-labeled samples post–streptavidin incu-
bation. The relative reduction (in optical density) of the MPB-labeled
sample as compared to the non–MPB-labeled sample indicates the
relative amount of 2GPI with free thiols labeled with MPB. Values
are the mean  SD.
2778 IOANNOU ET ALlevels, in the absence of further confounding effects. The
association was stronger when the comparison was with
the control group consisting of patients with auto-
immune disease with or without aPL (OR 4.6 [95% CI
2.9–7.5]). It is also possible to treat total 2GPI as a
continuous variable in the model. When this was done,
the results were consistent with the other findings (i.e.,
there was a strong positive association between total
2GPI level and thrombosis risk).
Figure 2B shows that elevated 2GPI levels were
observed only when persistent aPL positivity was com-
bined with a thrombotic event, thus fulfilling classifica-
tion criteria for APS. Levels of 2GPI in the auto-
immune disease controls (without thrombotic events)
with persistent aPL did not differ from levels in auto-
immune disease controls without aPL, and also were not
different from levels in healthy controls.
Subgroup analysis of the total level of 2GPI
within the APS group revealed no differences be-
tween those with and those without an additional auto-
immune disease. Furthermore, there was no differ-
ence between those with arterial thrombosis and those
with venous thrombosis (Supplementary Figure 3, http://
onlinelibrary.wiley.com/journal/10.1002/(ISSN)1529-
0131).
APS is associated with a greater proportion of
2GPI being in an oxidized state. Each patient sample
was labeled with MPB, and the amount of 2G P Ii nt h e
reduced form was compared and expressed as a percent-
age of that observed in a pooled standard (derived from
10 healthy volunteers who were matched for age and sex
with the APS group), after correction for the total
amount of 2GPI. The same in-house pooled standard
was used for every MPB labeling experiment and assay.
The sensitivity for detecting reduced 2GPI with this
assay extends to a dilution of 128,000-fold, indicating
marked sensitivity (Figure 3). The linear range was
found to be between dilutions of 400- and 128,000-fold.
The dilution found to yield 50% of maximum OD was
found to be 1:4,000, and hence this dilution was used to
screen all patient samples for reduced 2GPI. This assay
has previously been shown to yield identical results when
serum and plasma sampled from the same patient are
tested in parallel (13).
Figure 4 shows that the relative proportion of
2GPI in the reduced form, expressed as a percentage of
that observed with the in-house standard, was signifi-
cantly less in APS patients presenting with vascular
thrombosis as compared to healthy controls, auto-
immune disease controls, and clinical event controls (all
P  0.0001). Thus, 2GPI in APS patients presenting
with thrombosis is in an oxidized state relative to each of
the other 3 control groups. Similar to the findings in the
analysis of total 2GPI, a lower level of the reduced
2GPI (proportion 50%) was associated with a greater
risk of thrombosis. An OR of 4.1 (95% CI 1.9–8.8) in
relation to healthy subjects was observed after adjust-
ment for age and sex. A similar but somewhat smaller
effect (OR 2.0 [95% CI 1.2–3.4]) was also obtained when
the reference group was patients with autoimmune
disease with or without aPL but without thrombosis.
Patient positivity for lupus anticoagulant (LAC)
activity has been reported to be a strong predictor of
thrombosis compared to anti-2GPI or anticardiolipin
antibodies without LAC activity, particularly with regard
to arterial thrombosis and the development of stroke
(4,20). Subgroup analysis of the various aPL subtypes
within the APS group revealed that the proportion of
2GPI circulating in the reduced state was significantly
lower in the APS patients who were positive for both
anti-2GPI and LAC as compared to those positive for
anti-2GPI but not LAC (median 53.58% [IQR 39.18–
73.56] [n  45] versus 74.80% [IQR 60.69–84.51] [n 
Figure 3. High level of sensitivity of the assay for quantifying relative
amounts of reduced 2GPI. Pooled human serum from healthy
volunteers (n  10) was labeled with MPB, and a streptavidin-coated
plate–based enzyme-linked immunosorbent assay for reduced 2GPI
was performed on varying dilutions of this labeled sample, as described
in Patients and Methods. The linear range for this assay was at
dilutions between 1:400 and 1:128,000. OD  optical density (see
Figure 1 for other definitions).
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were also lower in APS patients presenting with arterial
thrombosis only (median 53.81% [IQR 39.38–74.62]
[n  67]) versus those presenting with venous thrombo-
sis only (62.09% [IQR 49.64–83.11] [n  59]) (P 
0.045), as shown in Supplementary Figure 4, http://
onlinelibrary.wiley.com/journal/10.1002/(ISSN)1529-
0131.
DISCUSSION
This is, to our knowledge, the first reported
demonstration that the redox state of the autoantigen
2GPI, in conjunction with plasma concentration levels,
is different in APS patients compared to healthy or
disease control subjects. Our study is the first to defini-
tively confirm that 2GPI levels are elevated in APS
patients—both those with and those without an addi-
tional autoimmune disease—as compared to healthy and
disease control groups. The finding of elevated levels of
2GPI was observed by our group previously, albeit
utilizing far lower numbers of patients (19). In addition,
it is reported herein that levels of oxidized 2GPI are
elevated in APS patients compared to healthy and
disease controls. A novel assay to measure relative
amounts of reduced 2GPI, as well as the ELISA for
total 2GPI, had good reproducibility and demonstrated
strong associations with the APS disease phenotype. The
robust nature of these findings is highlighted by the large
numbers of well-characterized patients (450) screened
through this large international collaborative multi-
center effort coupled with the use of both healthy and 2
distinct disease control groups. Such assays that precisely
quantify the amount of posttranslationally modified
autoantigen are unique in the field of APS, and even
autoimmunity.
An extensive number of in vitro and in vivo
studies suggest that anti-2GPI autoantibodies in com-
plex with 2GPI directly contribute to the APS clinical
phenotype of thrombosis (5). In the present study, we
Figure 5. Association of positivity for anti-2GPI combined with
lupus anticoagulant (LAC) with an elevated proportion of 2GPI
circulating in an oxidized state. Samples from APS patients presenting
with vascular thrombosis who were positive for both anti-2GPI and
LAC had significantly lower amounts of 2GPI in the reduced form as
compared to those from patients who were positive for anti-2GPI but
not for LAC. Data are presented as box plots, where the boxes
represent the 25th to 75th percentiles, the lines within the boxes
represent the median, and the lines outside the boxes represent the
10th and 90th percentiles. Circles indicate outliers. See Figure 2 for
other definitions.
Figure 4. Circulation of 2GPI in an oxidized form in patients with
APS. Levels of 2GPI in the reduced form were assayed and expressed
as a percentage of that observed in an in-house standard (pooled
serum from 10 healthy volunteers) after correction for the total
amount of 2GPI. The same pooled standard was used throughout.
APS patients presenting with thrombosis had significantly lower
amounts of 2GPI in the reduced form as compared to each of the 3
control groups. Data are presented as box plots, where the boxes
represent the 25th to 75th percentiles, the lines within the boxes
represent the median, and the lines outside the boxes represent the
10th and 90th percentiles. Circles indicate outliers. See Figure 2 for
definitions.
2780 IOANNOU ET ALhave demonstrated that patients who are persistently
positive for aPL and have the clinical features of APS
have higher levels of total and oxidized 2GPI compared
to controls. It is reasonable to hypothesize that clinical
states associated with an increased oxidative stress load,
such as pregnancy and infection (21), may lead to further
increases in the levels of oxidized 2GPI in the plasma,
potentially elevating the risk of pathologic thrombosis in
patients who are positive for anti-2GPI antibodies. This
is based on the premise that an increased plasma load of
oxidized 2GPI may lower the threshold for provoking
an anti-2GPI autoantibody–mediated dysregulated
prothrombotic response. A recent study demonstrated
that oxidative stress may drive 2GPI production in vivo
through activator protein 1 and NF-B–mediated up-
regulation of 2GPI gene promoter activity (22). Hence,
an enhanced oxidative stress load may increase antigenic
load, potentially driving anti-2GPI production in
autoimmunity-prone subjects and lowering the thresh-
old for a clinical event. This hypothesis supports a
rationale as to why SLE in particular is associated with
anti-2GPI antibodies, given that this condition is char-
acterized by a propensity toward autoreactivity, B cell
hyperactivity, and oxidative stress (23,24).
It was recently shown that 2GPI with free thiols
protects endothelial cells against oxidative stress–
induced cell injury, whereas oxidized 2GPI (which lacks
free thiols) has no such protective effect (13). Given the
present finding that a significant proportion of circulat-
ing 2GPI is in this protective reduced form in healthy
individuals, it may be reasonable to hypothesize that the
relative abundance of oxidized 2GPI in APS lowers the
threshold for development of vascular thrombosis. If this
hypothesis is correct, then one would expect elevated
levels of oxidized 2GPI to represent an independent
risk factor for thrombosis. Analysis of posttranslational
modifications of 2GPI on patient samples collected
prospectively and subsequent determination of the pres-
ence or absence of a thrombotic event would allow for
predictive calculations that could be used to test such a
hypothesis.
With the development of novel assays to detect
and quantify plasma 2GPI–related redox changes, it is
expected that stratification of anti-2GPI antibody–
positive individuals for thrombotic risk according to the
levels of total, reduced, and oxidized 2GPI may be
possible, with the attendant potential opportunity for
implementing medical prophylactic measures during
these periods of elevated risk. Prospective longitudinal
studies aimed at validating the predictive and diagnostic
role of such an approach are needed.
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